1例支原体肺炎并发人丙种球蛋白非敏感型川崎病患儿的药学监护

Pharmaceutical Care for a Child with Mycoplasma Pneumonia Complicating with Human Immunoglobulin(pH4) for Intravenous Injection Non-sensitive Type Kawasaki Disease

目的:探讨临床药师参与支原体肺炎并发川崎病(KD)患儿治疗的药学监护切入点。方法:以1例支原体肺炎并发KD患儿的治疗为例,根据抗菌药物、人丙种球蛋白(IVIG)、非甾体类抗炎药、糖皮质激素具体用药情况,结合患儿临床表现与病情变化,以药物相互作用、药品不良反应、用药注意事项、出院宣教等作为切入点开展全程化药学监护。结果:临床药师针对可能发生的不良反应采取联合用药措施早预防、采取监护措施早发现早干预,能及时发现问题,避免不良反应的发生,提高患儿依从性。结果:临床药师在治疗团队中深入开展药学监护并找准切入点,有利于提高临床治疗水平,从而更好地保障患儿用药安全。

OBJECTIVE：To investigate the breakthrough point of clinical pharmacists participating in the treatment for a child with Mycoplasma pneumonia complicating with Kawasaki disease,and standardize pharmaceutical care mode. METHODS：Taking a case of Mycoplasma pneumonia complicating with Kawasaki disease as example,according to the use of antibiotics,human immunoglobulin（p H4）for intravenous injection,non-steroidal anti-inflammatory drugs（NSAIDS）,glucocorticoids,combined with clinical manifestations and disease,whole course pharmaceutical care was conducted,using drug interaction,ADR,precautions,discharge education as breakthrough points. RESULTS：In view of possible ADR,clinical pharmacists adopted combination measures for early prevention,and monitoring measures for early identification and intervention to find problems in time,prevent the occurrence of ADR and improve patient compliance. CONCLUSIONS：What clinical pharmacists carry out pharmaceutical care in the treatment group is beneficial to improve the level of clinical treatment,so as to better safeguard patients＇ medication safety.